PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 88 filers reported holding PMV PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $235,026 | -82.4% | 145,078 | -81.5% | 0.00% | – |
Q1 2024 | $1,336,183 | -40.4% | 785,990 | +8.6% | 0.00% | – |
Q4 2023 | $2,242,707 | -46.0% | 723,454 | +6.9% | 0.00% | – |
Q3 2023 | $4,154,478 | +3.4% | 676,625 | +5.5% | 0.00% | – |
Q2 2023 | $4,016,297 | +8.6% | 641,581 | -17.2% | 0.00% | – |
Q1 2023 | $3,696,750 | -93.6% | 775,000 | -88.3% | 0.00% | -100.0% |
Q4 2022 | $57,545,906 | +24.1% | 6,614,472 | +69.7% | 0.00% | -33.3% |
Q3 2022 | $46,375,000 | -37.1% | 3,897,050 | -24.6% | 0.00% | -25.0% |
Q2 2022 | $73,694,000 | +38.0% | 5,171,490 | +101.6% | 0.00% | +33.3% |
Q1 2022 | $53,415,000 | +37.9% | 2,565,545 | +53.0% | 0.00% | +50.0% |
Q4 2021 | $38,724,000 | -28.5% | 1,676,355 | -7.8% | 0.00% | -33.3% |
Q3 2021 | $54,187,000 | +61.0% | 1,818,342 | +84.5% | 0.00% | +50.0% |
Q2 2021 | $33,664,000 | +67.8% | 985,488 | +61.5% | 0.00% | +100.0% |
Q1 2021 | $20,067,000 | +57.3% | 610,120 | +194.1% | 0.00% | 0.0% |
Q4 2020 | $12,760,000 | – | 207,453 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |